Skip to main content
60°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Equillium Inc
(NQ:
EQ
)
1.560
+0.020 (+1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Equillium Inc
< Previous
1
2
3
4
5
Next >
Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients
March 23, 2022
Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
March 17, 2022
Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...
Via
Benzinga
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition
February 16, 2022
Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal,...
Via
Benzinga
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Provides Timing Update on Conference Presentations
February 15, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 09, 2022
From
Equillium, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
January 21, 2022
Gainers Mustang Bio (NASDAQ:MBIO) shares ...
Via
Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022
From
Equillium, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Wednesday
January 05, 2022
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...
Via
Benzinga
45 Biggest Movers From Yesterday
January 05, 2022
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...
Via
Benzinga
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium To Reassess Potential For Its Asthma Trials
January 04, 2022
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target...
Via
Benzinga
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
December 13, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
November 10, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
November 09, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
November 04, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients
November 02, 2021
Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were...
Via
Benzinga
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
November 02, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
October 18, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
September 30, 2021
From
Equillium, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021
From
Equillium, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
September 15, 2021
Upgrades For Alcoa Corp (NYSE:
Via
Benzinga
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Equillium, Inc.
Via
Business Wire
60 Biggest Movers From Yesterday
August 24, 2021
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,...
Via
Benzinga
Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
August 12, 2021
Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.